PTGX — Protagonist Therapeutics, Inc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1377121 ·
Last close
$124.67
Market Cap
$8.07B
52W High
$160.81
52W Low
$77.00
ADV30
673,093
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 274,410,000 | 273,310,000 | 218,332,000 | 220,015,000 | 1,146,551,000 | 498,298,000 | 61,641,000 |
| Jun 2026 | 213,475,000 | — | 158,766,000 | 162,849,000 | 885,544,000 | 420,078,000 | 44,001,000 |
| Mar 2026 | 56,368,000 | — | -3,648,000 | 3,783,000 | 697,459,000 | 193,712,000 | 41,986,000 |
| Dec 2025 | 7,437,000 | — | -50,355,000 | -44,384,000 | 668,188,000 | 128,390,000 | 53,481,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$131,197,000
Investing CF
$78,722,000
Financing CF
$41,613,000
CapEx
$-615,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$1.03
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-304,039,000
Inventory
—
Receivables
$19,642,000
ST Investments
$362,498,000
EBIT TTM
$58,342,000
Pretax Income TTM
$84,338,000
Interest Exp TTM
—
Analysts
14
Yahoo Snapshot (yfinance, live)
Total Revenue
$551,689,984
EBITDA
$324,662,016
Free Cash Flow
$96,145,752
Enterprise Value
$7,770,721,792
Total Cash
$782,576,000
Total Debt
$9,216,000
Shares Out
64,708,285
Trailing EPS
$4.73
Book Value
$13.01
ROE
11.0%
ROA
4.5%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 46,016,000 | -158,127,000 | -130,149,000 | 668,188,000 | 53,481,000 | 614,707,000 | 57,671,000 |
| Dec 2024 | 434,433,000 | 252,843,000 | 275,188,000 | 744,725,000 | 69,430,000 | 675,295,000 | 184,152,000 |
| Dec 2023 | 60,000,000 | -93,652,000 | -78,955,000 | 357,951,000 | 21,274,000 | 336,677,000 | -70,236,000 |
| Dec 2022 | 26,581,000 | -131,373,000 | -127,393,000 | 247,928,000 | 32,320,000 | 215,608,000 | -108,137,000 |
TTM Snapshot
Revenues TTM
$281,992,000
NetIncome TTM
$82,909,000
OpCashFlow TTM
—
Assets (Latest)
$885,544,000
Forward EPS
$0.23
Max Pain — expiry 2027-01-15
max pain strike: $105.00 · spot: $127.16 · call oi: 59 · put oi: 1,533
Expected Move to 2027-01-15:
±$19.60
(15.41%) —
implied range
$107.56 –
$146.76
· ATM straddle on $125.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RYTM | RHYTHM PHARMACEUTICALS, INC. | $8.08B | $116.61 | — |
| CORT | CORCEPT THERAPEUTICS INC | $7.67B | $70.07 | — |
| ALKS | Alkermes plc. | $7.64B | $45.45 | — |
| PRAX | Praxis Precision Medicines, Inc. | $8.53B | $305.06 | — |
| SMMT | Summit Therapeutics Inc. | $8.53B | $10.67 | — |
News headlines (Yahoo Finance, 1h cache)
How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 37.6%
2026-11-16 13:55 · Yahoo
Protagonist Therapeutics (PTGX) Stock Looks Priced At A Premium As Its 7x Three Year Run Continues
2026-11-06 17:15 · Yahoo
Earnings Beat Might Change The Case For Investing In Protagonist Therapeutics Stock
2026-11-06 12:17 · Yahoo
Protagonist Therapeutics (PTGX) Swung To Profit, Is It A Bargain Or Fully Priced?
2026-11-06 11:13 · Yahoo
Protagonist Therapeutics (PTGX) Q3 Earnings and Revenues Surpass Estimates
2026-11-05 21:45 · Yahoo
Protagonist Therapeutics: Q3 Earnings Snapshot
2026-11-05 21:22 · Yahoo
Protagonist Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-05 21:05 · Yahoo
Protagonist Therapeutics (PTGX) to Report Q3 Results: Wall Street Expects Earnings Growth
2026-10-29 13:00 · Yahoo
Wall Street Analysts See a 25.34% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?
2026-10-28 12:55 · Yahoo
Protagonist Therapeutics to Participate in Four Investment Bank Conferences in November 2026
2026-10-27 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.